









Markets
/
Stocks
/
nasdaq-mgnx
/

MacroGenics Inc

MGNX

1.620USD

-0.110-6.36%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

102.39MMarket Cap

LossP/E TTM



MacroGenics Inc

1.620

-0.110-6.36%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

111 / 506

Overall Ranking

214 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Hold

Current Rating

3.400

Target Price

+96.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Fairly Valued

The company’s latest PE is -2.85, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 54.16M shares, decreasing 30.81% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.21M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.44.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.96, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 22.24M, representing a year-over-year increase of 105.99%, while its net profit experienced a year-over-year increase of 34.88%.

Score

Industry at a Glance

Previous score

7.96

Change



Financials

6.47

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.18

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.86

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.31

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -3.04, which is -45.09% below the recent high of -1.67 and -2.49% above the recent low of -3.12.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 111/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.86, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for MacroGenics Inc is 3.00, with a high of 5.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.86

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Hold

Current Rating

3.400

Target Price

+96.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

MacroGenics Inc

MGNX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.37, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.15 and the support level at 1.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.37

Change

-0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.044

Neutral

RSI(14)

48.363

Neutral

STOCH(KDJ)(9,3,3)

39.116

Buy

ATR(14)

0.168

Low Volatility

CCI(14)

-38.271

Neutral

Williams %R

78.947

Sell

TRIX(12,20)

0.023

Sell

StochRSI(14)

62.830

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.582

Buy

MA10

1.636

Sell

MA20

1.714

Sell

MA50

1.631

Sell

MA100

1.562

Buy

MA200

2.041

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 85.84%, representing a quarter-over-quarter decrease of 3.36%. The largest institutional shareholder is The Vanguard, holding a total of 4.21M shares, representing 6.67% of shares outstanding, with 2.99% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bellevue Asset Management AG

9.93M

Armistice Capital LLC

6.30M

+0.32%

The Vanguard Group, Inc.

Star Investors

4.43M

+2.53%

Wasatch Global Investors Inc

Star Investors

3.25M

-6.83%

Frazier Life Sciences Management, L.P.

3.18M

Acadian Asset Management LLC

2.31M

+78.84%

Millennium Management LLC

1.72M

-39.81%

BlackRock Institutional Trust Company, N.A.

4.50M

-3.17%

Koenig (Scott)

1.37M

+45.23%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.